52 results
8-K
EX-10.2
PCSA
Processa Pharmaceuticals Inc
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory … investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether … or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
8-K
EX-10.1
raf2y7kq1l29wkm4zp
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-99.1
9h44zcshf eqmo99
3 Nov 14
Separation and Severance Agreement
12:00am
8-K
EX-1.1
qqxj zgnu
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
8-K
EX-99.2
mfpo4rzjczf3p
9 Jan 14
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.1
qi01wtz 9vwugi0z8q
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-1.1
hy3b9iexdkov pxx0
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.2
8qkv7
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.1
ase7 0n2t5qizaz
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-10.2
5jbpks
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-4.2
jt057lsl
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am